Avidity Biosciences’ (RNA) Buy Rating Reiterated at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a research note published on Friday morning,Benzinga reports. They currently have a $65.00 price objective on the biotechnology company’s stock. RNA has been the subject of several other reports. HC Wainwright reissued a “buy” rating and issued a $72.00 […]

Mar 3, 2025 - 07:52

Chardan Capital reaffirmed their buy rating on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a research note published on Friday morning,Benzinga reports. They currently have a $65.00 price objective on the biotechnology company’s stock. RNA has been the subject of several other reports. HC Wainwright reissued a “buy” rating and issued a $72.00 […]